Volume 2 Supplement 1
Report of a Scientific Working Group on Serious Adverse Events following Mectizan treatment of onchocerciasis in Loa loa endemic areas
Reviews
This review is part of a collection of working papers first presented at the Scientific Working Group on Serious Adverse Events following Mectizan treatment of onchocerciasis in Loa loa endemic areas, held between 28 - 30 May 2002 at Shrigley Hall Hotel, Manchester, UK. The meeting was sponsored by the Mectizan® Donation Program, Merck & Co., Inc., and GlaxoSmithKline and and was kindly hosted by the Lymphatic Filariasis Support Centre, Liverpool School of Tropical Medicine.
Manchester, UK28 - 30 May 2002
-
Citation: Filaria Journal 2003 2(Suppl 1):S1
-
Report of a Scientific Working Group on Serious Adverse Events following Mectizan® treatment of onchocerciasis in Loa loa endemic areas
The occurrence of Serious Adverse Experiences (SAEs) following Mectizan® treatment of onchocerciasis in Loa loa endemic areas has been increasingly reported over the past decade. These SAEs include a severely dis...
Citation: Filaria Journal 2003 2(Suppl 1):S2 -
Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases
This paper presents a summary of reported cases of Serious Adverse Events (SAEs) following treatment with Mectizan® (ivermectin, Merck, Sharpe & Dohme) in onchocerciasis mass treatment programs from January 1, 19...
Citation: Filaria Journal 2003 2(Suppl 1):S3 -
Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon
In August 2002, 65 cases of Loa-associated neurological Serious Adverse Events were reported after ivermectin treatment. The first signs, occurring within the 12–24 hours following treatment, included fatigue, ge...
Citation: Filaria Journal 2003 2(Suppl 1):S4 -
Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
Reactions are commonly associated with the chemotherapy of onchocerciasis. However unmanageable reactions are uncommon when ivermectin (Mectizan®) is used for the treatment of this infection, and this drug has pr...
Citation: Filaria Journal 2003 2(Suppl 1):S5 -
Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
Ivermectin (Mectizan®) is the only drug currently recommended for the treatment and control of onchocerciasis. Serious adverse events rarely occur during treatment, except in subjects heavily infected with Loa Lo...
Citation: Filaria Journal 2003 2(Suppl 1):S6 -
Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future
Of the 207 Serious Adverse Events (SAEs) following treatment with Mectizan® (ivermectin, Merck, Sharpe & Dohme) that were reported from 1989 to 2001 through the passive SAE surveillance system required of all onc...
Citation: Filaria Journal 2003 2(Suppl 1):S7 -
Ivermectin: does P-glycoprotein play a role in neurotoxicity?
The macrocyclic lactone ivermectin (Mectizan®) is widely used for the control of human filarial infections, particularly as a donated product for onchocerciasis and lymphatic filariasis. In the case of control of...
Citation: Filaria Journal 2003 2(Suppl 1):S8 -
A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa
The occurrence of Loa loa encephalopathy following mass treatment of onchocerciasis with Mectizan® has adversely affected onchocerciasis control efforts in central Africa. Persons with very high densities of L. l...
Citation: Filaria Journal 2003 2(Suppl 1):S9 -
Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis
In areas co-endemic for loiasis and onchocerciasis, the classic Community-Directed Treatment using ivermectin (Mectizan®) must be adapted as additional program activities, better communication and tighter control...
Citation: Filaria Journal 2003 2(Suppl 1):S10